Ariceum和Eckert & Ziegler签署治疗癌症放射性核素的协议,推进精密治疗。 Ariceum and Eckert & Ziegler sign deal for cancer-treating radionuclides, advancing precision treatments.

Aiceum治疗和Eckert & Ziegler已经签署了一项全球供应协定,用于治疗难以治疗的癌症的医疗放射性核素。 Ariceum Therapeutics and Eckert & Ziegler have signed a global supply agreement for medical radionuclides used in treating hard-to-treat cancers. Eckert & Ziegler将为Ariceum提供Actium-225和Lutetium-177,用于临床研究和未来商业阶段。 Eckert & Ziegler will supply Ariceum with Actinium-225 and Lutetium-177 for clinical studies and future commercial phases. 该协定支持发展精准癌症治疗方法,并有扩大至其他药物和放射性核素的备选办法。 The agreement supports the development of precision cancer treatments, with options for expanding to other drugs and radionuclides.